Evidence map›Paper›PMID 9614177›Full record

ArticleMolecular biology of the cell1998

ADP-ribosylation factor 1 transiently activates high-affinity adaptor protein complex AP-1 binding sites on Golgi membranes.

Y Zhu, L M Traub, S Kornfeld

Open access · greenAbstract read
In one paragraph

Article in Molecular biology of the cell, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Alternative Splicing in Ca(V)2.2 Regulates Neuronal Trafficking via Adaptor Protein Complex-1 Adaptor Protein Motifs.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. New links between vesicle coats and Rab-mediated vesicle targeting.Seminars in cell & developmental biology · 2011
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Membrane curvature induced by Arf1-GTP is essential for vesicle formation.Proceedings of the National Academy of Sciences of the United States of America · 2008
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Y ZhuDivision of Hematology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
L M Traub
S Kornfeld
Washington University in St. Louis · US

Funding

STRUCTURE, BIOSYNTHESIS &FUNCTION OF GLYCOPROTEINSR37CA008759 · NCI · WASHINGTON UNIVERSITY · PI KORNFELD, STUART A · 1990 to 2018
$14.0M
Structure, Biosynthesis & Function of GlycoproteinsR01CA008759 · NCI · WASHINGTON UNIVERSITY · PI KORNFELD, STUART A · 1985 to 2023
$3.5M
NCI NIH HHS R01 CA008759NCI NIH HHS R01 CA08759NHLBI NIH HHS HL0708823
6 · The paper itself

Abstract

Association of the Golgi-specific adaptor protein complex 1 (AP-1) with the membrane is a prerequisite for clathrin coat assembly on the trans-Golgi network (TGN). The AP-1 adaptor is efficiently recruited from cytosol onto the TGN by myristoylated ADP-ribosylation factor 1 (ARF1) in the presence of the poorly hydrolyzable GTP analog guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). Substituting GTP for GTPgammaS, however, results in only poor AP-1 binding. Here we show that both AP-1 and clathrin can be recruited efficiently onto the TGN in the presence of GTP when cytosol is supplemented with ARF1. Optimal recruitment occurs at 4 microM ARF1 and with 1 mM GTP. The AP-1 recruited by ARF1.GTP is released from the Golgi membrane by treatment with 1 M Tris-HCl (pH 7) or upon reincubation at 37 degreesC, whereas AP-1 recruited with GTPgammaS or by a constitutively active point mutant, ARF1(Q71L), remains membrane bound after either treatment. An incubation performed with added ARF1, GTP, and AlFn, used to block ARF GTPase-activating protein activity, results in membrane-associated AP-1, which is largely insensitive to Tris extraction. Thus, ARF1. GTP hydrolysis results in lower-affinity binding of AP-1 to the TGN. Using two-stage assays in which ARF1.GTP first primes the Golgi membrane at 37 degreesC, followed by AP-1 binding on ice, we find that the high-affinity nucleating sites generated in the priming stage are rapidly lost. In addition, the AP-1 bound to primed Golgi membranes during a second-stage incubation on ice is fully sensitive to Tris extraction, indicating that the priming stage has passed the ARF1.GTP hydrolysis point. Thus, hydrolysis of ARF1.GTP at the priming sites can occur even before AP-1 binding. Our finding that purified clathrin-coated vesicles contain little ARF1 supports the concept that ARF1 functions in the coat assembly process rather than during the vesicle-uncoating step. We conclude that ARF1 is a limiting factor in the GTP-stimulated recruitment of AP-1 in vitro and that it appears to function in a stoichiometric manner to generate high-affinity AP-1 binding sites that have a relatively short half-life.

Indexed as

Adaptor Protein Complex alpha SubunitsAdaptor Proteins, Vesicular TransportADP-Ribosylation Factor 1ADP-Ribosylation FactorsAnimalsBinding SitesCell ExtractsClathrinCoated VesiclesFluorescent Antibody Technique, IndirectGolgi ApparatusGTP-Binding ProteinsGuanosine 5'-O-(3-Thiotriphosphate)HydrolysisIntracellular MembranesMaleAdaptor Protein Complex alpha SubunitsAdaptor Proteins, Vesicular TransportADP-Ribosylation Factor 1ADP-Ribosylation FactorsCell ExtractsClathrinGTP-Binding ProteinsGuanosine 5'-O-(3-Thiotriphosphate)Membrane ProteinsTromethamine

Identifiers

PMID9614177
PMCPMC25353
OpenAlexW2150058209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.